1. Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs relative to age- and gender-matched general population norms.
Spydergram of mean SF-36 domain scores at baseline and weeks 12 (A) and 24 (B) for sarilumab 150 mg and 200 mg+csDMARDs compared with placebo+csDMARDs relative to age- and gender-matched general population norms. All scores on a scale of 0 to 100 (0=worst, 100=best). For week 12, n=181 for placebo, n=165 for sarilumab 150 mg and n=184 for sarilumab 200 mg; for week 24, n=99 for placebo, n=126 for sarilumab 150 mg and n=135 for sarilumab 200 mg. BP, Bodily Pain; GH, General Health Perceptions; MH, Mental Health; NS, not significant; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality.
Vibeke Strand et al. RMD Open 2017;3:e000416
Copyright © BMJ Publishing Group & EULAR. All rights reserved.